With reference to the earlier intimation dated May 12, 2014, Cipla has now informed that Cipla (EU), UK (‘Cipla UK’), a wholly owned subsidiary of the Company, has pursuant to the approval of the board of Cipla UK, made an additional investment of USD 3 million in Chase Pharmaceuticals Corporation Inc., US (‘Chase’) towards full settlement of its obligation under the agreed arrangement for investment in Chase. Consequently, Cipla UK’s total investment in Chase would aggregate to approximately USD 5.12 million for a 16.7% stake on a fully diluted basis.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1620.00 |
| Dr. Reddys Lab | 1316.35 |
| Cipla | 1294.95 |
| Zydus Lifesciences | 927.80 |
| Lupin | 2296.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: